Immunoliposomes for Cancer Treatment

Advances in Pharmacology

Volumn 40, Issue C, 1997, Pages 399-435

  Park, John W ^a   Hong, Keelung ^b   Kirpotin, Dmitri B ^b   Papahadjopoulos, Demetrios ^b   Benz, Christopher C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; DRUG CARRIER; LIPOSOME;

ANIMAL; EXPERIMENTAL NEOPLASM; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; REVIEW;

ANIMALS; ANTIBODIES, NEOPLASM; DRUG CARRIERS; HUMANS; IMMUNOTHERAPY; LIPOSOMES; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0030627930     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60146-5     Document Type: Article

References (119)

1. Ahmad I., and Allen T.M. Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro. Cancer Res. 52 (1992) 4817-4820
2. Ahmad I., Longenecker M., Samuel J., and Allen T.M. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res. 55 (1993) 1484-1488
3. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., and Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237 (1995) 99-108
4. Anderson W.F. Human gene therapy. Science 256 (1992) 808-813
5. Arscott P.G., Li A.-Z., and Bloomfield A. Condensation of DNA by trivalent cations. 1. Effects of DNA length and topology on the size and shape of condensed particles. Biopolymers 30 (1990) 619-630
6. Baselga J., Norton L., Shalaby R., and Mendelsohn J. Anti-HER2 humanized monoclonal antibody (MAb) alone and in combination with chemotherapy against breast carcinoma xenografts. Proc. Am. Soc. Clin. Oncol. (1994) 63
7. HER2 monoclonal antibody in patients with HER/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14 (1996) 737-744
8. Batra J.K., Kasprzyk P.G., Bird R.E., Pastan I., and King C.R. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin. Proc. Natl. Acad. Set. U.S.A. 89 (1992) 5867-5871
9. Berchuck A., Kamel A., Whitaker R., Kerns B., Olt G., Kinney R., Soper J.T., Dodge R., Clarke-Pearson D.L., Marks P., McKenzie S., Yin S., and Bast R.C. Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50 (1990) 4087-4091
10. Berchuck A., Rodriguez G., Kinney R.B., Soper J.T., Dodge R.K., Clarke-Pearson D.L., and Bast R.C. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J. Obstet. Gynecol. 164 (1991) 15-21
11. Bookstein R., Demers W., Gregory R., Maneval D., Park J.W., and Wills K. p53 gene therapy in vivo of hepatocellular and liver-metastatic colorectal cancer. Semin. Oncol. 23 (1996) 66-77
12. Calabretta B. Inhibition of protooncogene expression by antisense oligodeoxynucleotides: Biological and therapeutic implications. Cancer Res. 51 (1991) 4505-4510
13. Carraway K.L., and Cantley L.C. A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling. Cell 78 (1994) 5-8
14. Carter P., Presta L., Gorman CM., Ridgway J.B.B., Henner D., Wong W.L.T., Rowland A.M., Kotts C., Carver M.E., and Shepard H.M. Humanization of an antip185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4285-4289
15. Carter P., Rodrigues M.L., Park J.W., and Zapata G. Preparation and uses of Fab' fragments from E. coli. In: McCafferty H.H.R., and Chiswell D.J. (Eds). "Antibody Engineering: A Practical Approach" (1996), IRL Press, Oxford, UK. 291-308
16. Chua M.M., Fan S.T., and Karush F. Attachment of immunoglobulin to liposomal membrane via protein carbohydrate. Biochim. Biopbys. Acta 800 (1984) 291-300
17. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., and Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256 (1992) 1550-1552
18. Daleke D.L., Hong K., and Papahadjopoulos D. Endocytosis of liposomes by macrophages: Binding, acidification and leakage of liposomes monitored by a new fluorescence assay. Biochim. Biophys. Acta 1024 (1990) 352-366
19. Deshane J., Siegal G.P., Alvarez R.D., Wang M.H., Feng M., Cabrera G., Liu T., Kay M., and Curiel D.T. Targeted tumor killing via an intracellular antibody against erbB-2. J. Clin. Invest. 96 (1995) 2980-2989
20. Dietrich C., Boscheinen O., Scharf K.-D., Schmitt L., and Tampe R. Functional immobilization of a DNA-binding protein at a membrane interface via histidine tag and synthetic chelator lipids. Biochemistry 35 (1996) 1100-1105
21. Emanuel N., Kedar E., Bolotin E.M., Smorodinsky N.I., and Barenholz Y. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes. Pharm. Res. 13 (1996) 352-359
22. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz M., Northrop J.P., Ringold G.M., and Danielsen M. Lipofection: A highly efficient, lipid mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7413-7417
23. Fendly B.M., Winget M., Hudziak R.M., Lipari M.T., Napier M.A., and Ullrich A. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50 (1990) 1550-1558
24. Fominaya J., and Wels W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein: Novel non-viral gene delivery system. J. Biol. Chem. 371 (1996) 1-9
25. Fraley R., Subramani S., Berg P., and Papahadjopoulos D. Introduction of liposome-encapsulated SV40 DNA into cells. J. Biol. Chem. 255 (1980) 10431-10435
26. Frebourg T., and Friend S.H. The importance of p53 gene alterations in human cancer: Is there more than circumstantial evidence?. J. Natl. Cancer Inst. 85 (1993) 1554-1557
27. Friend D.S., Papahadjopoulos D., and Debs R.J. Endocytosis and intracellular processing accompanying transfection mediated by cationic liposomes. Biochim. Biophys. Acta 1278 (1996) 41-50
28. Fujiwara T., Cai D.W., Georges R.N., Mukhopadhyay T., Grimm E.A., and Roth J.A. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J. Natl. Cancer Inst. 86 (1994) 1458-1462
29. Gabizon A., and Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6949-6953
30. Gabizon A., Shiota R., and Papahadjopoulos D. Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times. J. Natl. Cancer Inst. 81 (1989) 1484-1488
31. Gregoriadis G. The carrier potential of liposomes in biology and medicine. N. Engl. J. Med. 295 (1976) 704-710
32. Gregoriadis G., and Neerunjun E.D. Homing of liposomes to target cells. Biochem. Biophys. Res. Commun. 65 (1975) 537-544
33. Han X., Kasahara N., and Kan Y.W. Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 9747-9751
34. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., and Allen T.M. Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239 (1995) 133-144
35. Hashimoto Y., Sugawara M., Kamiya T., and Suzuki S. Targeting of monoclonal antibody-coated liposomes to sheep red blood cells. Biochem. Biophys. Res. Commun. 103 (1986) 1069-1076
36. Harsch M., Walther P., Weder H.G., and Hengartner H. Targeting of monoclonal antibody-coated liposomes to sheep red blood cells. Biochem. Biophys. Res. Commun. 103 (1981) 1069-1076.
37. Hashimoto K., Loader J.E., and Kinsky S.C. Iodoacetylated and biotinylated liposomes: Effect of spacer length on sulfhydryl ligand binding and avidin precipitibility. Biochim. Biophys. Acta 856 (1986)
38. Hashimoto Y., Sugawara M., Kamiya T., and Suzuki S. Coating of liposomes with subunits of monoclonal IgM antibody and targeting of the liposomes. In: Langoneand J.J., and Van Vunakis H. (Eds). "Methods in Enzymology" 121 (1986), Academic Press, New York 817-828.
39. Heath T.D. Covalent attachment of proteins to lipopsomes. In: Widder K.J., and Green R. (Eds). Methods in Enzymology 149 (1987), Academic Press, Orlando, Florida. 111-119
40. Hoffman R.M., Margolis L.B., and Bergelson L.D. Binding and entrapment of high molecular weight DNA by lecithin liposomes. FEBS Lett. 93 (1978) 365-368
41. Hong K., Zheng W., Baker A., and Papahadjopoulos D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)-phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett. 400 (1997) 233-237
42. Huang A., Tsao Y.S., Kennel S., and Huang L. Characterization of antibody covalently coupled to liposomes. Biochim. Biophys. Acta 716 (1982) 140-150
43. Huang S.K., Lee K.D., Hong K., Friend D.S., and Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 52 (1992) 5135-5143
44. Huang S.K., Mayhew E.M., Gilani S., Lasic D.D., Martin F.J., and Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res. 52 (1992) 6774-6781
45. Hynes N.E., and Stern D.F. The biology of erbR-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta 1198 (1994) 165-184
46. Jones M.N., and Hudson M.J.H. The targeting of immunoliposomes to tumour cells (A431) and the effects of encapsulated methotrexate. Biochim. Biophys. Acta 1152 (1993) 231-242
47. Keinanen K., and Laukkanen M.-L. Biosynthetic lipid-tagging of antibodies. FEBS Lett. 346 (1994) 123-126
48. Kern J.A., Schwartz D.A., Nordberg J.E., Weiner D.B., Greene M.L., Torney L., and Robinson R.A. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 50 (1990) 5184-5191
49. Kirpotin D., Park J.W., Hong K., Zalipsky S., LI W.L., Carter P., Benz C.C., and Papahadjopoulos D. Sterically stabilized anti-HER2 immunoliposomes: Design and targeting to human breast cancer cell in vitro. Biochemistry 36 (1997) 66-75
50. Klibanov A.L., Maruyama K., Kecklerberg A.M., Torchilin V.P., and Huang L. Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta 1062 (1991) 142-148
51. Lasic D.D., and Martin F.J. "Stealth Liposomes." (1995), CRC Press, Boca Raton, Florida.
52. Lasic D.D., and Papahadjopoulos D. Liposomes revisited. Science 267 (1995) 1275-1276
53. Laukkanen M.-L., Alfthan K., and Keinanen K. Functional immunoliposomes harboring a biosynthetically lipid-tagged single-chain antibody. Biochemistry 33 (1994) 11664-11670
54. Leserman L., and Machy P. Ligand targeting of liposomes. In: Ostro M.J. (Ed). "Liposomes: From Biophysics to Therapeutics" (1987), Dekker, New York 157-194
55. Lewis G.D., Figari L., Fendly B., Wong W.L., Carter P., Gorman C., and Shepard H.M. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol, lmmunother. 37 (1993) 255-263
56. Liu E., Thor A., He M., Barcos M., Ljung B.-M., and Benz C. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7 (1992) 1027-1032
57. Loughrey H., Bally M.B., and Cullis P.R. A non-covalent method of attaching antibodies to liposomes. Biochim. Biopbys. Acta 901 (1987) 157-160
58. Marquet R., and Houssier C. Thermodynamics of cation-induced DNA condensation. J. Biomol. Struct. Dyn. 9 (1991) 159-167
59. Martin F.J., and Papahadjopoulos D. Irreversible coupling of immunoglobulin fragments to preformed vesicles: An improved method for liposome targeting. J. Biol. Chem. 257 (1982) 286-288
60. Martin F.J., Hubbell L.W., and Papahadjopoulos D. Immunospecific targeting of liposomes to cells: A novel and efficient method for covalent attachment of Fab fragments via disulfide bonds. Biochemistry 20 (1981) 4429-4438
61. Michael S.I., and Curiel D.T. Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther. 1 (1994) 223-232
62. Miller A.D. Human gene therapy comes of age. Nature (London) 357 (1992) 455-460
63. Miller D.G., Adam M.A., and Miller A.D. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol. 10 (1990) 4239-4242
64. Mori A., Klibanov A.L., Torchilin V.P., and Huang L. Influence of the steric barrier of amphipathic poly(ethylene glycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett. 284 (1991) 263-266
65. Mori A., Kennel S.J., and Huang L. Immunotargeting of liposomes containing lipophilic antitumor prodrugs. Pharm. Res. 10 (1993) 507-514
66. Mori A., Kennel S.J., van Waalkes M.B., Scherphof G.L., and Huang L. Characterization of organ-specific immunoliposomes for delivery of 3, 5-O-dipalmitoyl-5-fluoro-2-deoxyridine in a mouse lung-metastasis model. Cancer Chemother. Pharmacol. 35 (1995) 447-456
67. Morishige H., Ohkuma T., and Kaji A. In vitro cytostatic effect of TNF (tumor necrosis factor) entrapped in immunoliposomes on cells normally insensitive to TNF. Biochim. Biopbys. Acta 1151 (1993) 59-68
68. Muss H.B., Thor A.D., Berry D.A., Kute T., Liu E.T., Koerner F., Cirrincione C.T., Budman D.R., Wood W.C., Barcos M., and Henderson I.C. c-erbB-2 expression and response to adjuvant chemotherapy in women with node-positive early breast cancer. N. Engl. J. Med. 330 (1994) 1260-1266
69. Nassander U.K., Steerenberg P.A., Poppe H., Storm G., Poels L.G., Jong W.H.D., and Crommelin D.J.A. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice. Cancer Res. 52 (1992) 646-653
70. Nassander U.K., Steerenberg P.A., Jong W.H.D., Overveld W.O.W.M.V., Boekhorst C.M.E.T., Poels L.G., Jap P.H.K., and Storm G. Design of immunoliposomes directed against human ovarian carcinoma. Biochim. Biophys. Acta 1235 (1995) 126-139
71. Niehans G.A., Singleton T.P., Dykoski D., and Kiang D.T. Stability of HER-2/neu expression over time and at multiple metastatic sites. J. Natl. Cancer Inst. 85 (1993) 1230-1235
72. O'Connell R.P., Carter P., Presta L., Eigenbrot C., Covarrubias M., Snedecor B., Speckart R., Blank G., Vetterlein D., and Kotts C. Characterization of humanized anti-p185HER2 antibody Fab fragments produced in E. coli. In: Cleland J.L. (Ed). "Protein Folding in Vivo and in Vitro" (1993), American Chemical Society, Washington, D. C. 218-239
73. Oldfield E.H., Ram Z., Culver K.W., and Blaese R.M. Clinical protocol: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous gancyclovir. Hum. Gene Ther. 4 (1993) 39-69
74. Papahadjopoulos D., Allen T.M., Gabizon A., Mayhew E., Matthay K., Huang S.K., Lee K.D., Woodle M.C., Lasic D.D., Redemann C., and Martin F.J. Sterically stabilized liposomes: Improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 11460-11464
75. Park J.-B., Rhim J.S., Park S.-C., Kimm S.-W., and Kraus M.H. Amplification, overexpression, and rearrangement of the erbB-2 proto-oncogene in primary human stomach carcinomas. Cancer Res. 49 (1989) 6605-6609
76. Park J.W., Stagg R., Lewis G.D., Carter P., Maneval D., Slamon D.J., Jaffe H., and Shepard H.M. Anti-p185HER2 monoclonal antibodies: Biological properties and potential for immunotherapy. In: Dickson R.B., and Lippman M.E. (Eds). "Genes, Oncogenes, and Hormones: Advances in Cellular and Molecular Biology of Breast Cancer" (1992), Kluwer Academic Publishers, Boston. 193-211
77. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., Wirth C., Shalaby R., Kotts C., Wood W.I., Papahadjopoulos D., and Benz C.C. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 1327-1331
78. Park J.W., Hong K., Zheng W., Benz C.C., and Papahadjopoulos D. Development of liposome- and anti-HER2 immunoliposome-plasmid complexes for efficient and selective gene delivery. Proc. Amer. Assoc. Cancer Res. 38 (1997) 342
79. Parr M.J., Ansell S.M., Choi L.S., and Cullis P.R. Factors influencing the retention and chemical stability of poly(ethylene glycol)-lipid conjugates incorporated in large unilamellar vesicles. Biochim. Biophys. Acta 1195 (1994) 21-30
80. Pegram M., Lipton A., Pietras R., Hayes D., Weber B., Baselga J., Tripathy D., Twaddell T., Glaspy J., and Slamon D. Phase II study of intravenous recombinant humanized anti-p185 HER-2 monoclonal antibody (rhuMAb HER-2) plus cisplatin in patients with HER-2/neu overexpressing metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 14 (1995) 106
81. Phillips N.C., and Emili A. Immunogenicity of immunoliposomes. Immunol. Lett. 30 (1991) 291-296
82. Phillips N.G., and Tsoukas C. Immunoliposome targeting to CD4+ cells in human blood. Cancer Detect. Prev. 14 (1990) 383-390
83. Phillips N.C., Gagne L., Tsoukas C., and Dahman J. Immunoliposome targeting to murine CD4+ leucocytes is dependent on immune status. J. Immunol. 152 (1994) 3168-3174
84. Pietras R.J., Fendly B.M., Chazin V.R., Pegram M.D., Howell S.B., and Slamon D.J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene 9 (1994) 1829-1838
85. Plum G.E., Arscott P.G., and Bloomfield V.A. Condensation of DNA by trivalent cations. 2. Effects of cation structure. Biopolymers 30 (1990) 631-643
86. Press M.F., Cordon-Cardo C., and Slamon D.J. Expression of the HER-2/neu protooncogene in normal human adult and fetal tissues. Oncogene 5 (1990) 953-962
87. Ram Z., Culver K.W., Walbridge S., Blaese R.M., and Oldfield E.H. In situ retroviral mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53 (1993) 83-88
88. Ranade V. Drug delivery systems. 1. Site-specific drug delivery using liposomes as carriers. J. Clin. Pharmacol. 29 (1989) 685-694
89. Rodrigues M.L., Presta L.G., Kotts C.E., Wirth C., Mordenti J., Osaka G., Wong W.L., Nuijens A., Blackburn B., and Carter P. Development of a humanized disulfidestabilized anti-p185HER2 Fv-β-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug. Cancer Res. 55 (1995) 63-70
90. Roth J.A., and Cristiano R.J. Gene therapy for cancer: What have we done and where are we going?. J. Natl. Cancer Inst. 89 (1997) 21-39
91. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., Hong W.K., Komaki R., Lee J.J., Nesbitt J.C., Pisters K.M.W., Putnam J.B., Schea R., Shin D.M., Walsh G.L., Dolormente M.M., Han C.-I., Martin F.D., Xu K., Stephens L.C., McDonnell T.J., Mukhopadhyay T., and Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat. Med. 2 (1996) 985-991
92. Sarup J.C., Johnson R.M., King K.L., Fendly B.M., Lipari M.T., Napier M.A., Ullrich A., and Shepard H.M. Characterization of an anti-p185 HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul. 1 (1991) 72-82
93. Shalaby M.R., Shepard H.M., Presta L., Rodrigues R.L., Beverley P.L., Feldmann M., and Carter P. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 175 (1992) 217-225
94. Shaw P., Bovey R., Tardy S., Sahli R., Sordat B., and Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4495-4499
95. Shepard H.M., Lewis G.D., Sarup J.C., Fendly B.M., Maneval D., Mordenti J., Figari I., Kotts C.E., Palladino M.A., Ullrich A., and Slamon D. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 11 (1991) 117-127
96. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., and McGuire W.L. Human breast cancer: Correlation of relapse and survival with amplification of HER2/neu oncogene. Science 235 (1987) 177-182
97. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., and Press M. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (1989) 707-712
98. Straubinger R.M., Lopez N.G., Debs R.J., Hong K., and Papahadjopoulos D. Liposome-based therapy of human ovarian cancer: Parameters determining potency of negatively charged and antibody-targeted liposomes. Cancer Res. 48 (1988) 5237-5245
99. Stribling R., Brunette E., Liggitt D., Gaensler K., and Debs R. Aerosol gene delivery in vivo. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 11277-11281
100. Suzuki S., Watanabe S., Uno S., Tanaka M., Masuko T., and Hashimoto Y. Endocytosis does not necessarily augment the cytotoxicity of Adriamycin encapsulated in immunoliposomes. Biochim. Biophys. Acta 1224 (1994) 445-453
101. Suzuki S., Uno S., Fukuda Y., Aoki Y., Masuko T., and Hashimoto Y. Cytotoxicity of anti-c-erbB-2 immunoliposomes containing doxorubicin on human cancer cells. Br. J. Cancer 72 (1995) 663-668
102. Thomas J.A., Chai Y.C., and Jung C.H. Protein S-thiolation and dethiolation. In: Packer L. (Ed). Methods in Enzymology 233 (1994), Academic Press, San Diego, California. 385-395
103. Torchilin V.P. Immunoliposomes and PEGylated immunoliposomes: Possible use for targeted delivery of imaging agents. Immunomethods 4 (1994) 244-258
104. Valone F.H., Kaufman P.A., Guyre P.M., Lewis L.D., Memoli V., Deo Y., Graziano R., Fisher J.L., Meyer L., Mrozek-Orlowski M., Wardwell K., Guyre V., Morley T.L., Arvizu C., and Fanger M.W. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpress the protooncogene HER2/neu. J. Clin. Oncol. 13 (1995) 2281-2292
105. VandeVijver M.J., Peterse M.L., Mooi W.J., Wisman P., Lomans J., Dalesio O., and Nusse R. Neu-protein expression in breast cancer. N. Engl. J. Med. 319 (1988) 1239-1245
106. Vile R., and Russell S.J. Gene transfer technologies for the gene therapy of cancer. Gene Ther. 1 (1994) 88-98
107. Waldmann T. Monoclonal antibodies in diagnosis and therapy. Science 252 (1991) 1657-1662
108. Wang C.-Y., and Huang L. pH-sensitive immunoliposomes mediate target-cell-specific delivery and controlled expression of a foreign gene in mouse. Proc. Natl. Acad. Sci. U.S.A. 84 (1987) 7851-7855
109. Weiner L.M., Holmes M., Adams G.P., LaCreta F., Watts P., and Garcia de Palazzo I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD 16. Cancer Res. 53 (1993) 94-100
110. Weissig V., Lasch J., Klibanov A.L., and Torchilin V.P. A new hydrophobic anchor for the attachment of proteins to liposomal membranes. FEBS Lett. 202 (1986) 86-90
111. Wels W., Harwerth I.-M., Mueller M., Groner B., and Hynes N.E. Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Res. 52 (1992) 6310-6317
112. Wolff B., and Gregoriadis G. The use of monoclonal anti-thy-1 IgG for the targeting of liposomes to AKR-A cells in vitro and in vivo. Biochim. Biophys. Acta 802 (1984) 259-273
113. Yanagie H., Tomita T., Kobayashi H., Fujii Y., Takahashi T., Hasumi K., and Nariuchi H. Application of boronated anti-CEA immunoliposome to tumour cell growth inhibition in in vitro boron neutron capure therapy model. Br. J. Cancer 63 (1991) 522-526
114. Yokota J., Yamamoto T., Miyajima N., Toyoshima K., Nomura N., Sakamoto H., Yoshida T., Terada M., and Sugimura T. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 2 (1988) 283-287
115. Yonemura Y., Ninomiya I., Yamaguchi A., Fushida S., Kimura H., Ohoyama S., Miyazaki I., Endou Y., Tanaka M., and Sasaki T. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 51 (1991) 1034-1038
116. Zalipsky S., Hansen C.B., Menezes D.L.D., and Allen T.M. Long-circulating, polyethylene glycol-grafted immunoliposomes. J. Controlled Release 39 (1996) 153-161
117. Zhau H.E., Zhang X., von Eschenbach A.C., Scorsone K., Babaian R.J., Ro J.Y., and Hung M.-C. Amplification and expression of the c-erbB-2/neu proto-oncogene in human bladder cancer. Mol. Carcinog. 3 (1990) 254-257
118. Zhau H.E., Wan D.S., Zhou J., Miller G.J., and von Eschenbach A.C. Expression of c-erbB-2/neu proto-oncogene in human prostatic cancer tissues and cell lines. Mol. Carcinog. 5 (1992) 320-327
119. Zhu N., Liggitt D., Liu Y., and Debs R. Systemic gene expression after intravenous DNA delivery into adult mice. Science 261 (1993) 209-211